Swiss pharma giant Roche (ROG: SIX) will increase the level of localization in Russia through the establishment of full cycle of production of its Gaziva /Gazyvaro (obinutuzumab) antitumor drug, according to the company.
Production will take place at the facilities of the Bashkir plant of Pharmstandard, a Russian partner of Roche. First sales will be started in early 2019, reports The Pharma Letter’s local correspondent.
The amount of investments in the project will be 2.5 billion roubles ($43.5 million). The new drug is designed for treatment of chronic lymphocytic leukemia and follicular lymphoma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze